FibroBiologics, Inc. 8-K

What Happened

• FibroBiologics, Inc. announced on April 20, 2026 (via an 8-K and press release) that Nasdaq has formally confirmed the company has evidenced compliance with applicable requirements for continued listing on The Nasdaq Capital Market and that the previously disclosed listing matter has been closed.
• Nasdaq previously notified the company on April 17, 2026 that FibroBiologics demonstrated compliance with the bid price requirement (Nasdaq Listing Rule 5550(a)(2)), and on March 9, 2026 that it demonstrated compliance with the stockholders’ equity requirement (Nasdaq Listing Rule 5550(b)(1)).

Key Details

• Date of press release/Regulation FD disclosure: April 20, 2026 (Exhibit 99.1 filed).
• Nasdaq confirmed compliance with the Bid Price Rule on April 17, 2026 and with the Equity Rule on March 9, 2026.
• The company is subject to a Mandatory Panel Monitor for one year from April 17, 2026 for the Bid Price Rule and for one year from March 9, 2026 for the Equity Rule.
• If FibroBiologics fails to maintain compliance during the monitoring period, Nasdaq staff will issue a delist determination without providing a cure period; the company may request a hearing to stay delisting while the hearing process proceeds.

Why It Matters

• This filing lowers the immediate risk of delisting by confirming Nasdaq has closed the prior listing matter, which can reassure investors about the company’s continued presence on The Nasdaq Capital Market.
• However, the one-year Mandatory Panel Monitor means the company remains under heightened scrutiny: failure to remain in compliance during that period could lead promptly to a delist determination (though the company can seek a hearing).
• Investors should watch future updates on the company’s stock price (relevant to the bid price rule) and equity/financial condition (relevant to the equity rule) for signs of ongoing compliance.